Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09248-6
Abstract: ObjectiveThe efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported;… read more here.
Keywords: treatment; ocrelizumab versus; efficacy; multiple sclerosis ... See more keywords